GSK plc (LON:GSK) Insider Buys £99,671 in Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($18.08) per share, for a total transaction of £99,671 ($129,258.20).

GSK Stock Down 3.1 %

Shares of LON GSK opened at GBX 1,407 ($18.25) on Thursday. GSK plc has a 12-month low of GBX 1,371.40 ($17.78) and a 12-month high of GBX 1,823.50 ($23.65). The company has a market capitalization of £57.41 billion, a PE ratio of 1,245.13, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The firm’s 50-day moving average is GBX 1,549.30 and its two-hundred day moving average is GBX 1,596.52.

GSK Announces Dividend

The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be issued a GBX 15 ($0.19) dividend. This represents a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK’s dividend payout ratio (DPR) is presently 5,309.73%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, August 28th. Berenberg Bank reissued a “buy” rating and set a GBX 1,820 ($23.60) price objective on shares of GSK in a report on Tuesday, September 10th. Citigroup decreased their price objective on shares of GSK from GBX 2,120 ($27.49) to GBX 1,900 ($24.64) and set a “buy” rating on the stock in a report on Friday, July 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,850 ($23.99) price objective on shares of GSK in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Monday, July 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 1,842.50 ($23.89).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.